Analysts Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $11.90

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has received a consensus rating of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $11.90.

A number of research firms recently weighed in on NMTC. Zacks Research lowered shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th. JonesTrading started coverage on shares of NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st.

Insider Buying and Selling

In other news, insider David J. Wambeke bought 166,666 shares of NeuroOne Medical Technologies stock in a transaction on Sunday, March 1st. The stock was acquired at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the completion of the acquisition, the insider owned 166,666 shares of the company’s stock, valued at $669,997.32. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 2,438 shares of company stock valued at $11,702 in the last ninety days. Insiders own 11.80% of the company’s stock.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Large investors have recently added to or reduced their stakes in the company. Focus Financial Network Inc. bought a new position in NeuroOne Medical Technologies in the third quarter worth about $31,000. Legato Capital Management LLC bought a new position in NeuroOne Medical Technologies in the fourth quarter worth about $34,000. Squarepoint Ops LLC bought a new position in NeuroOne Medical Technologies in the fourth quarter worth about $36,000. Susquehanna International Group LLP purchased a new position in NeuroOne Medical Technologies during the 3rd quarter worth $47,000. Finally, XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies during the 2nd quarter worth $51,000. 16.07% of the stock is currently owned by institutional investors.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $4.75 on Tuesday. NeuroOne Medical Technologies has a 1-year low of $3.27 and a 1-year high of $6.96. The company has a 50-day moving average of $4.49 and a 200 day moving average of $4.64. The firm has a market cap of $40.00 million, a PE ratio of -4.66 and a beta of 0.63.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The company had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million. Sell-side analysts anticipate that NeuroOne Medical Technologies will post -0.72 EPS for the current fiscal year.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.